| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01662505 | Leukemia, Myeloid, Acute | Drug: Volasertib | Boehringer Ingelheim | Phase 1 | 2012-08-01 | 2015-07-30 |
| NCT01348347 | Neoplasms | Drug: Volasertib, low dose, d1q3w|Drug: Volasertib, middle dose, d1q3w|Drug: Volasertib, high dose, d1q3w | Boehringer Ingelheim | Phase 1 | 2011-04-01 | 2014-08-06 |
| NCT02722135 | Leukemia, Myeloid, Acute | Drug: Volasertib | Boehringer Ingelheim | Phase 1 | 2016-11-01 | 2017-01-26 |
| NCT02003573 | Leukemia, Myeloid, Acute | Drug: decitabine iv|Drug: volasertib iv infusion | Boehringer Ingelheim | Phase 1 | 2014-01-01 | 2016-12-14 |
| NCT01145885 | Neoplasms | Drug: BI 6727 | Boehringer Ingelheim | Phase 1 | 2010-06-01 | 2013-10-31 |
| NCT01772563 | Neoplasms | Drug: volasertib|Drug: itraconazole | Boehringer Ingelheim | Phase 1 | 2013-02-01 | 2017-02-14 |
| NCT02905994 | AML | Drug: Volasertib|Drug: Cytarabine|Drug: Idarubicin|Procedure: Bone Marrow Biopsy | Massachusetts General Hospital|Boehringer Ingelheim | Phase 1 | 2016-09-01 | 2017-02-15 |
| NCT02527174 | Leukemia, Myeloid, Acute|Leukemia, Monocytic, Acute|Leukemia, Myelomonocytic, Acute|Leukemia, Erythroblastic, Acute|Leukemia, Megakaryoblastic, Acute | Drug: Volasertib|Drug: Idarubicin|Drug: Cytarabine | University of Alberta | Phase 1 | 2016-11-01 | 2016-10-26 |
| NCT02861040 | Recurrent Adult Acute Lymphoblastic Leukemia|Refractory Adult Acute Lymphoblastic Leukemia | Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Vincristine Sulfate Liposome|Drug: Volasertib | Northwestern University|National Comprehensive Cancer Network|National Cancer Institute (NCI) | Phase 1 | 2016-08-01 | 2016-12-13 |
| NCT00969761 | Neoplasms | Drug: BI-6727|Drug: BI 6727 | Boehringer Ingelheim | Phase 1 | 2009-08-01 | 2012-07-25 |
| NCT02201329 | Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic | Drug: Azacitidine|Drug: Volasertib | Boehringer Ingelheim | Phase 1 | 2014-08-01 | 2015-09-30 |
| NCT02875002 | Relapsed and Refractory Aggressive B- and T-cell Lymphomas|Lymphoma | Drug: volasertib|Drug: belinostat | Yale University|Massey Cancer Center|Sidney Kimmel Comprehensive Cancer Center | Phase 1 | 2016-10-01 | 2016-08-23 |
| NCT02721875 | Myelodysplastic Syndromes | Drug: Volasertib|Drug: Volasertib|Drug: Azacitidine | Boehringer Ingelheim | Phase 1 | 2016-04-01 | 2016-12-19 |
| NCT02198482 | Acute Myeloid Leukemia (AML)|High-risk Myelodysplastic Syndrome (MDS) | Drug: Volasertib|Drug: Cytarabine|Drug: Daunorubicin|Drug: Mitoxantrone | University of Ulm | Phase 2 | 2016-02-01 | 2016-12-02 |
| NCT02757248 | PTCL|CTCL | Drug: Volasertib|Drug: Romidepsin | Anne Beaven, MD|National Comprehensive Cancer Network|Boehringer Ingelheim|Duke University | Phase 1 | 2016-11-01 | 2016-11-29 |
| NCT01022853 | Neoplasms | Drug: BI 6727|Drug: BIBF 1120 | Boehringer Ingelheim | Phase 1 | 2009-12-01 | 2013-11-01 |
| NCT01206816 | Neoplasms | Drug: BI 6727 + BIBW 2992 | Boehringer Ingelheim | Phase 1 | 2010-10-01 | 2013-10-31 |
| NCT01957644 | Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic | Drug: Azacitidine|Drug: Volasertib | Boehringer Ingelheim | Phase 1 | 2013-11-01 | 2017-01-10 |
| NCT00824408 | Carcinoma, Non-Small-Cell Lung | Drug: pemetrexed|Drug: pemetrexed|Drug: BI 6727 | Boehringer Ingelheim | Phase 2 | 2009-03-01 | 2016-07-28 |
| NCT00804856 | Leukemia, Myeloid, Acute | Drug: BI 6727 (d1 and 15)|Drug: BI 6727 (d1 and 15)|Drug: Cytarabine|Drug: Cytarabine | Boehringer Ingelheim | Phase 2 | 2008-11-01 | 2016-08-22 |
| NCT01721876 | Leukemia, Myeloid, Acute | Drug: placebo|Drug: volasertib|Drug: low dose cytarabine|Drug: low dose cytarabine | Boehringer Ingelheim | Phase 3 | 2013-01-01 | 2016-08-22 |
